<DOC>
	<DOCNO>NCT00126880</DOCNO>
	<brief_summary>The study measure safe effective AVX754 ( new drug treatment HIV ) treat HIV-1 infected people fail treatment lamivudine .</brief_summary>
	<brief_title>AVX754 ( New Nucleoside Reverse Transcriptase Inhibitor NRTI ) Treat Drug-resistant HIV</brief_title>
	<detailed_description>Lamivudine emtricitabine commonly use combination drug first-line treatment HIV infection . Although effective initially , many people later develop resistance drug ( include lamivudine ) lead virological failure . Resistance associate characteristic mutation , lamivudine M184V mutation . A change new , active drug must take place patient fail current regime , regain control virus . Although type drug available second line treatment , currently fully active , well tolerated cytidine analogue replace lamivudine second-line regimen patient fail first line treatment . This study measure efficacy safety AVX754 ( novel cytidine analogue activity HIV resistant nucleoside ) part new regimen treat patient fail treatment contain lamivudine , compare best alternative new regimen continue include lamivudine .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HIV1 infect M184V mutation reverse transcriptase Currently take lamivudine Viral load &gt; 2000 copies/ml Hepatitis B surface antigen positive Pregnant breastfeeding female Hepatitis C RNA positive requiring treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>anti-retroviral therapy</keyword>
	<keyword>nucleoside analogue</keyword>
	<keyword>reverse transcriptase</keyword>
	<keyword>lamivudine</keyword>
	<keyword>resistance mutation</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>